Key result
Extended-release niacin/laropiprant 2 g significantly improved lipid parameters, including an 18.4% reduction in LDL-C versus placebo, and produced significantly less flushing than ERN alone.
Why the study?
Does extended-release niacin/laropiprant improve lipid parameters and reduce flushing compared to extended-release niacin or placebo in patients with primary hypercholesterolaemia or mixed dyslipidaemia?
Population
1,613 patients with primary hypercholesterolaemia or mixed dyslipidaemia
Comparison
Extended-release niacin/laropiprant 1 g for 4… vs Extended-release niacin 1 g then 2 g, or placebo
Design
RCT, randomised
Follow-up
24 weeks
Authors
Loading...
ERN/laropiprant improves lipids with less flushing than ERN; confirms RCT benefits for tolerability in hypercholesterolemia.
RCT (n=1,613)
Does extended-release niacin/laropiprant improve lipid parameters and reduce flushing compared to extended-release niacin or placebo in patients with primary hypercholesterolaemia or mixed dyslipidaemia?
Extended-release niacin/laropiprant significantly improves lipid profiles and reduces niacin-induced flushing compared to extended-release niacin alone.
Maccubbin et al. (2008) conducted an RCT in Dyslipidaemia (n=1,613). Extended-release niacin/laropiprant vs. Extended-release niacin or placebo was evaluated on Change in LDL-C versus placebo. Extended-release niacin/laropiprant 2 g significantly improved lipid parameters, including an 18.4% reduction in LDL-C versus placebo, and produced significantly less flushing than ERN alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: